Synthesis of alkyl 6-methyl-4-(2-pyridyl)-1,2,3,4-tetrahydro-2<i>H</i>-pyrimidine-2-one-5-carboxylates for evaluation as calcium channel antagonists
作者:Kuljeet Kaur、Edward E. Knaus
DOI:10.1002/jhet.5570440339
日期:2007.5
(1), urea (2) and an alkyl acetoacetate (3) afforded the respective alkyl (Me, Et, i-Pr, i-Bu, t-Bu) 6-methyl-4-(2-pyridyl)-1,2,3,4-tetrahydro-2H-pyrimidine-2-one-5-carboxylates (4a-e). The most potent calcium channel antagonist ethyl 6-methyl-4-(2-pyridyl)-1,2,3,4-tetrahydro-2H-pyrimidine-2-one-5-carboxylate (4b, IC50 = 1.67 × 10−5 M) wasa much weaker calcium channel antagonist than the reference drug
Bigenelli酸催化2-吡啶基甲醛(1),尿素(2)和乙酰乙酸烷基酯(3)的缩合反应,分别得到烷基(Me,Et,i -Pr,i -Bu,t -Bu)6-甲基-4 -(2-吡啶基)-1,2,3,4-四氢-2 H-嘧啶-2-一-5-羧酸酯(4a-e)。最有效的钙通道拮抗剂乙基6-甲基-4-(2-吡啶基)-1,2,3,4-四氢-2 H-嘧啶-2-一-5-羧酸酯(4b,IC 50 = 1.67×10 -5 M)的钙通道拮抗剂比参考药物硝苯地平弱得多(Adalat®,IC 50= 1.40×10 -8 M)在豚鼠回肠纵向平滑肌(GPILSM)上。烷基6-甲基-4-(2-吡啶基)-1,2,3,4-四氢-2 H-嘧啶-2-一-5-羧酸盐对心脏没有任何正性肌力作用,因为没有增加或减少,在豚鼠左心房的收缩力中观察到。这些结构活性研究表明,烷基6-甲基-4-(2-吡啶基)-1,2,3,4-四氢-2 H-嘧